Form 4: ResMed CEO Michael Farrell Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 9, 2024, Michael J. Farrell, the CEO of ResMed Inc., executed options to acquire 14,683 shares of ResMed Common Stock at a price of $84.98 per share.
- Simultaneously, Farrell sold 14,683 shares of ResMed Common Stock at a weighted average price of $248.3791, with individual sales prices ranging from $245.90 to $254.06.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on January 31, 2024.
- Following these transactions, Farrell directly owns 464,169 shares of ResMed Common Stock and indirectly owns 4,090 shares through the Lisette and Michael Farrell Family Trust.
- He also directly owns 29,366 ResMed Common Stock Options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It is common for executives to utilize Rule 10b5-1 plans to manage their stock holdings and avoid accusations of trading on non-public information. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across publicly traded companies, particularly in the healthcare and technology sectors.
- Companies like Philips and Medtronic, which are competitors of ResMed, also have executives who utilize similar trading plans to manage their equity holdings.
- The use of Rule 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved compared to the total outstanding shares.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| 11/11/2018 | Date options first became exercisable. |
| 01/31/2024 | Date Rule 10b5-1 plan was adopted. |
| 09/09/2024 | Date of option exercise and stock sale. |
| 09/10/2024 | Date of signature on the SEC Form 4. |
| 11/16/2024 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.